MX2022002239A - Glicovariantes de igm. - Google Patents

Glicovariantes de igm.

Info

Publication number
MX2022002239A
MX2022002239A MX2022002239A MX2022002239A MX2022002239A MX 2022002239 A MX2022002239 A MX 2022002239A MX 2022002239 A MX2022002239 A MX 2022002239A MX 2022002239 A MX2022002239 A MX 2022002239A MX 2022002239 A MX2022002239 A MX 2022002239A
Authority
MX
Mexico
Prior art keywords
igm
heavy chain
variant
derived
motif
Prior art date
Application number
MX2022002239A
Other languages
English (en)
Spanish (es)
Inventor
Bruce Keyt
Ramesh Baliga
Dean Ng
Original Assignee
Igm Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igm Biosciences Inc filed Critical Igm Biosciences Inc
Publication of MX2022002239A publication Critical patent/MX2022002239A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2022002239A 2019-08-23 2020-08-21 Glicovariantes de igm. MX2022002239A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962891263P 2019-08-23 2019-08-23
PCT/US2020/047495 WO2021041250A1 (en) 2019-08-23 2020-08-21 Igm glycovariants

Publications (1)

Publication Number Publication Date
MX2022002239A true MX2022002239A (es) 2022-03-22

Family

ID=74684266

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022002239A MX2022002239A (es) 2019-08-23 2020-08-21 Glicovariantes de igm.

Country Status (11)

Country Link
US (1) US20220306760A1 (enExample)
EP (1) EP4017533A4 (enExample)
JP (1) JP2022545682A (enExample)
KR (1) KR20220050166A (enExample)
CN (1) CN114269380A (enExample)
AU (1) AU2020337333A1 (enExample)
BR (1) BR112022003282A2 (enExample)
CA (1) CA3149350A1 (enExample)
IL (1) IL290253A (enExample)
MX (1) MX2022002239A (enExample)
WO (1) WO2021041250A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL292311A (en) 2014-04-03 2022-06-01 Igm Biosciences Inc J-chain qualified
JP7179464B2 (ja) 2015-01-20 2022-11-29 アイジーエム バイオサイエンシズ インコーポレイテッド 腫瘍壊死因子 （ｔｎｆ） スーパーファミリー受容体結合分子およびその使用
AU2016238246B2 (en) 2015-03-25 2021-05-13 Igm Biosciences, Inc. Multi-valent hepatitis B virus antigen binding molecules and uses thereof
CA2999284C (en) 2015-09-30 2023-06-13 Igm Biosciences A/S Binding molecules with modified j-chain
US11639389B2 (en) 2015-09-30 2023-05-02 Igm Biosciences, Inc. Binding molecules with modified J-chain
WO2020247929A1 (en) 2019-06-07 2020-12-10 Adimab, Llc High affinity anti-cd3 antibodies, and methods for their generation and use
CA3231006A1 (en) * 2021-09-17 2023-03-23 Adimab, Llc Anti-cd3 antibodies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG196697A1 (en) * 2007-03-22 2014-02-13 Biogen Idec Inc Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
EP2496600A1 (en) * 2009-11-04 2012-09-12 Fabrus LLC Methods for affinity maturation-based antibody optimization
IL292311A (en) * 2014-04-03 2022-06-01 Igm Biosciences Inc J-chain qualified
CA2999284C (en) * 2015-09-30 2023-06-13 Igm Biosciences A/S Binding molecules with modified j-chain
AU2016370821A1 (en) * 2015-12-18 2018-07-12 Biogen Ma Inc. Bispecific antibody platform
EP3571222A4 (en) * 2017-01-19 2021-06-16 Cedars-Sinai Medical Center METHOD BASED ON HIGHLY MULTIPLEX AND MASS SPECTROMETRY FOR MEASURING HUMAN 72 PROTEINS
EP3600442A1 (en) * 2017-03-22 2020-02-05 Genentech, Inc. Optimized antibody compositions for treatment of ocular disorders
CA3083363A1 (en) * 2017-12-01 2019-06-06 Novartis Ag Polyomavirus neutralizing antibodies

Also Published As

Publication number Publication date
BR112022003282A2 (pt) 2022-05-24
KR20220050166A (ko) 2022-04-22
CA3149350A1 (en) 2021-03-04
US20220306760A1 (en) 2022-09-29
CN114269380A (zh) 2022-04-01
WO2021041250A1 (en) 2021-03-04
EP4017533A4 (en) 2024-03-27
AU2020337333A1 (en) 2022-03-03
JP2022545682A (ja) 2022-10-28
IL290253A (en) 2022-04-01
EP4017533A1 (en) 2022-06-29

Similar Documents

Publication Publication Date Title
MY205343A (en) Anti-muc1 antibody
WO2020039321A8 (en) Anti-gdf15 antibodies, compositions and methods of use
MX2025002735A (es) Virus oncolitico que codifica un inhibidor de la molecula 4 asociada a linfocitos t citotoxicos (ctla-4) y su uso en el tratamiento de cancer
PH12021550361A1 (en) Anti-avb8 antibodies and compositions and uses thereof
BR112017019617A2 (pt) Anticorpo, composto conjugado anticorpo- fármaco anti-cd48, composição de conjugado anticorpo-fármaco, métodos para tratar um paciente com um câncer que expressa cd48, para produzir um anticorpo anti-cd48 e para produzir um conjugado anticorpo-fármaco anti-cd48, ácido nucléico isolado, vetor isolado, e, célula hospedeira isolada
MX2020008030A (es) Anticuerpos de glipicano 3 y conjugados de los mismos.
WO2019232244A3 (en) Antibody molecules to cd73 and uses thereof
ZA202206993B (en) Anti-lilrb1 antibody and uses thereof
PE20221008A1 (es) Anticuerpos anti-receptor de transferrina con afinidad disenada
EP4400517A3 (en) Insertable variable fragments of antibodies and modified a1-a2 domains of nkg2d ligands, and non-natural nkg2d ligands that bind non-natural nkg2d receptors
MX2018013038A (es) Anticuerpos anti-il-33, composiciones, metodos y usos de los mismos.
CL2012002433A1 (es) Anticuerpo aislado o fragmento inmunoreactivo del mismo que comprende un dominio variable que se une específicamente a un dominio extracelular del receptor b7-h3; ácido nucleico que lo codifica; hibridoma que lo secreta; reactivo de redireccionamiento de doble afinidad (dart) que lo comprende; composición farmacéutica que lo comprende; y su uso para tratar cáncer.
CO2019002369A2 (es) Anticuerpo que se une específicamente a pd-1 y fragmento funcional del mismo
BR112018003326A2 (pt) anticorpos de ligação de linfopoietina estromal tímica (tslp) e métodos de uso dos anticorpos
BR112022003282A2 (pt) Glicovariantes de igm
AU2018278730A1 (en) A novel anti-c-Met antibody and use thereof
PE20230381A1 (es) Proteina de union a rgma
PH12021553109A1 (en) Humanized antibody molecules to cd138 and uses thereof
MX2021000797A (es) Anticuerpos agonistas de cd226.
MX2023001041A (es) Anticuerpo anti-lilrb1 y usos del mismo.
WO2022031710A3 (en) Multispecific binding agents and uses thereof
MX2020010092A (es) Variantes de anticuerpo c-terminales.
MY208015A (en) Anti-human tlr7 antibody
EP4062934A4 (en) COMPOSITION FOR PREVENTING OR TREATING CANCER WITH ANTI-CD300C MONOCLONAL ANTIBODIES
WO2019133902A3 (en) Antibodies and assays for ccl14